BridgeBio Oncology Therapeutics, Inc. (BBOT)

NGM – Цена в реальном времени. Валюта: USD

9.22

+0.02 (0.22%)

Рынок открыт: Aug 12, 2026, 11:55 AM EDT

9.10

-0.10 (-1.09%)

Предыдущая сессия: Aug 11, 2026, 5:59 PM EDT

11.08.2026

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on August 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in July 2026.

11.08.2026

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Continued to advance monotherapy and combination cohorts for all clinical programs Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203 Presented preclinical data at AACR highlighting the potency and activity of BBO-11818 in KRAS mutant tumor models and the efficacy of BBO-10203 in combination with tucatinib and trastuzumab in HER2amp models Cash runway expected to fund operations into 2028 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

Видео

No Data

There is no data to display

Пресс-релизы

11.08.2026

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

11.08.2026

BridgeBio Oncology Therapeutics, Inc. (BBOT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

BridgeBio Oncology Therapeutics, Inc. (BBOT)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Видео

No Data

Пресс-релизы

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Видео

No Data

Пресс-релизы

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Search stocks

BridgeBio Oncology Therapeutics, Inc. (BBOT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

BridgeBio Oncology Therapeutics, Inc. (BBOT)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Видео

No Data

Пресс-релизы

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Видео

No Data

Пресс-релизы

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress